The short version of Neurotrophic factor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Beyond acting as the carrier protein for vitamin D and its metabolites, DBP also transports free fatty acids, binds to actin and may help prevent actin polymerization during tissue injury. It also might serve as a macrophage activator, contributing to the inflammatory response by modulating T-cell activity. As Gc protein-derived macrophage activating factor it is a Macrophage Activating Factor (MAF) that has been tested for use as a cancer treatment that would activate macrophages against cancer cells.
Alexander "Sascha" Zverev (born 20 April 1997) is a German professional tennis player. He has a career-high singles ranking of world No. 2 by the ATP, first achieved in June 2022. Zverev has won 26 ATP Tour singles titles, including two majors at the 2026 French Open and 2026 US Open, a gold medal at the 2020 Tokyo Olympics, seven ATP 1000 and the 2018 and 2021 ATP Finals. Zverev is a former junior world No. 1, and won a junior major singles title at the 2014 Australian Open. He had an early breakthrough on the professional tour, becoming one of the youngest ATP Challenger Tour title winners in history at the age of 17. As a teenager, Zverev won two ATP titles and upset then–world No. 3 Roger Federer on grass. At 20 years old, he became the youngest player to debut in the top 20 since Novak Djokovic. At the Laver Cup, Zverev played an instrumental role in Team Europe's early success, winning the clinching matches in 2018, 2019, and 2026. After reaching his first major final at the 2020 US Open, he became an Olympic gold medalist in 2021. He suffered an ankle injury at the 2022 French Open, which required an extended recovery period. He rebounded in the following years to re-enter the top 10, where he has since remained a permanent fixture and reached five more major finals. In 2026, Zverev enjoyed his most successful season winning the French Open and US Open.
The Zaporozhian Sich had its own authorities, its own "Lower" Zaporozhian Host, and its own land. In 1775, the Lower Dnieper Zaporozhian Host was destroyed. Later, its high-ranking Cossack leaders were exiled to Siberia, its last chief, Petro Kalnyshevsky, becoming a prisoner of the Solovetsky Islands. Some Cossacks moved to the Danube Delta region, where they established a new sich under Ottoman rule. To prevent further defection of Cossacks, the Russian government restored the special Cossack status of the majority of Zaporozhian Cossacks. This allowed them to unite in the Host of Loyal Zaporozhians, and later to reorganize into other hosts, of which the Black Sea Host was most important. Because of land scarcity resulting from the distribution of Zaporozhian Sich lands among landlords, they eventually moved on to the Kuban region. The majority of Danubian Sich Cossacks moved first to the Azov region in 1828, and later joined other former Zaporozhian Cossacks in the Kuban region. Groups were generally identified by faith rather than language in that period, and most descendants of Zaporozhian Cossacks in the Kuban region are bilingual, speaking both Russian and Balachka, the local Kuban dialect of central Ukrainian. Their folklore is largely Ukrainian. The predominant view of ethnologists and historians is that its origins lie in the common culture dating back to the Black Sea Cossacks.
=== Alcohol use === GGT is elevated by ingestion of large quantities of alcohol. However, determination of high levels of total serum GGT activity is not specific to alcohol intoxication, and the measurement of selected serum forms of the enzyme offer more specific information. Isolated elevation or disproportionate elevation compared to other liver enzymes (such as ALT or alanine transaminase) can indicate harmful alcohol use or alcoholic liver disease, and can indicate excess alcohol consumption up to 3 or 4 weeks prior to the test. The mechanism for this elevation is unclear. Alcohol might increase GGT production by inducing hepatic microsomal production, or it might cause the leakage of GGT from hepatocytes.
Another aspect that distinguishes sortases in general is that they have a very specific targeting for their substrate, as sortases have generally two functions, the first is the fusing of proteins to the cell wall of the bacteria and the second is the polymerization of pilin. For the process of localization of proteins to the cell wall there is three-fold requirement that the protein contain a hydrophobic domain, a positively charged tail region, and final specific sequence used for recognition. The best studied of these signals is the LPXTG, which acts as the point of cleavage, where the sortase attacks in between Thr and Gly, conjugating to the Thr carboxyl group. Then the thioester is resolved by the transfer of the peptide to a primary amine, and this generally has a very high specificity, which is seen in the example of B. cereus where the sortase D enzyme helps to polymerize the BcpA protein via two recognition signals, the LPXTG as the cleavage and thioester forming point, and the YPKN site which acts as the recognition signal as where the isopeptide will form. While the particulars may vary between bacteria, the fundamentals of sortase enzymatic chemistry remain the same. The next case is that of Transglutaminases (TGases), which act mainly within eukaryotes for fusing together different proteins for a variety of reasons such as a wound healing or attaching proteins to lipid membranes. The TGases themselves also contain their own 'catalytic triad' with Histidine, Aspartate, and Cysteine.
Sources: en.wikipedia.org
Severe aortic stenosis with or without symptoms Aortic regurgitation with NYHA functional class III-IV symptoms Mitral stenosis with NYHA functional class II-IV symptoms Mitral regurgitation with NYHA functional class III-IV symptoms Aortic and/or mitral valve disease resulting in severe pulmonary hypertension (pulmonary pressure greater than 75% of systemic pressures) Aortic and/or mitral valve disease with severe LV dysfunction (EF less than 0.40) Mechanical prosthetic valve requiring anticoagulation Marfan syndrome with or without aortic regurgitation
==== Regulation of biosynthesis ==== This pathway requires energy in order to occur; therefore, the presence of ATP activates the first enzyme of the pathway, ATP-phosphoribosyl transferase (shown as His1 in the image on the right). ATP-phosphoribosyl transferase is the rate determining enzyme, which is regulated through feedback inhibition, meaning that it is inhibited in the presence of the product, histidine.
== Conclusion == Owing to its non-specific cytotoxicity, instability under ambient conditions, and relative expense of isolation and manufacture, kedarcidin chromophore has not been investigated rigorously as a therapeutic candidate. However, the recent scientific advances discussed above have served to diminish this last hurdle, as fully synthetic and biosynthetic routes toward scalable kedarcidin production are now within reach. Moreover, with the rising popularity of antibody-drug conjugate therapies, toxicity liabilities may be mitigated through targeted delivery of this potent cytotoxin, potentially enabling efficient therapies that use minimal quantities of this complex material. The recent development of inotuzumab ozogamicin, a calicheamicin-based antibody-drug conjugate for the treatment of non-Hodgkin lymphoma, reinforces the potential of enediynes to find critical use in the treatment of human disease. Thus, the biological potential and complex molecular architecture of kedarcidin may likely inspire further scientific inquiry into this substance, and possibly deliver new ordnance in the war against cancer.
Plasmin is a serine protease that acts to dissolve fibrin blood clots. Apart from fibrinolysis, plasmin proteolyses proteins in various other systems: It activates collagenases, some mediators of the complement system, and weakens the wall of the Graafian follicle, leading to ovulation. Plasmin is also integrally involved in inflammation. It cleaves fibrin, fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin, like trypsin, belongs to the family of serine proteases. Plasmin is released as a zymogen called plasminogen (PLG) from the liver into the systemic circulation. Two major glycoforms of plasminogen are present in humans - type I plasminogen contains two glycosylation moieties (N-linked to N289 and O-linked to T346), whereas type II plasminogen contains only a single O-linked sugar (O-linked to T346). Type II plasminogen is preferentially recruited to the cell surface over the type I glycoform. Conversely, type I plasminogen appears more readily recruited to blood clots. In circulation, plasminogen adopts a closed, activation-resistant conformation. Upon binding to clots, or to the cell surface, plasminogen adopts an open form that can be converted into active plasmin by a variety of enzymes, including tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). Fibrin is a cofactor for plasminogen activation by tissue plasminogen activator. Urokinase plasminogen activator receptor (uPAR) is a cofactor for plasminogen activation by urokinase plasminogen activator.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.